SLC5A2 and type 2 diabetes mellitus: The introduction of sodium-glucose co-transporter-2 (SGLT2) inhibitors as the latest category of antidiabetic agents was evidenced by successful clinical trials of EMPAG-REG, DECLARE-TIMI 58, CANVAS, showing a reduction of major cardiovascular events in patients with T2DM (1–3).